Efficacy and safety outcomes from the MATISSE phase 3 trial of maternal bivalent RSVpreF vaccination among pregnant women vaccinated at 32 to 36 weeks of gestation. Swiss Medical Weekly, [S. l.], v. 156, n. 1, p. 4711, 2026. DOI: 10.57187/4711. Disponível em: https://smw.ch/index.php/smw/article/view/4711. Acesso em: 5 feb. 2026.